CRISPR-Cas 9 is a gene-editing tool that made it possible to rewrite any organism's genetic code and tackle genetic diseases more effectively. Known as genetic scissors, CRISPR identifies a DNA ...

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

When the gene editing tool CRISPR-Cas9 rocketed to fame more than a decade ago, it transformed biotechnology. Faster, cheaper, and safer than previous methods, the tool helped scientists gain insight ...

A novel CRISPR-based technology can spread within bacterial populations to eliminate antibiotic resistance.

Scientists from Mass General Brigham and the Broad Institute of MIT and Harvard have used CRISPR screens to identify genetic modifications that influence T cell function and survival in cultures and ...

Using CRISPR, Hebrew University of Jerusalem team finds PEDS1 enzyme linked to reduced brain size; study maps 331 genes ...

Muscles make up nearly 40% of the human body and power every move we make, from a child's first steps to recovery after injury. For some, however, muscle development goes awry, leading to weakness, ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

CRISPR Therapeutics (CRSP) earns a Hold rating as pipeline breadth grows but CASGEVY's launch remains slow and economically unattractive. CRSP’s in vivo editing platform shows strong early validation, ...